A PHASE 2, 12-WEEK, ADAPTIVE, OPEN LABEL, SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY, …10/17/2019 - 10/16/2024 (PI)
Pfizer, Inc
Investigating the functional capacity of autoantibodies in primary membranous nephropathy09/20/2021 - 06/30/2024 (PI)
National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS1R01DK126978-01A1
Redefining Membranous Nephropathy by Autoantibody-specific Subclassification01/22/2013 - 12/31/2018 (PI)
NIH-NIDDK1R01DK097053-03
Redifining Membranous Nephropathy by Autoantibody-specific Subclassification01/22/2013 - 12/31/2018 (PI)
NIH-NIDDK5R01DK097053-05
Investigation of Anti-PLA2R-Associated Membranous Nephropathy at the Molecular Level09/01/2011 - 06/30/2013 (PI)
The Halpin Foundation
Detection of anti-phospholipase A2 receptor autoantibodies in idiopathic membranous nephropathy07/01/2009 - 06/30/2013 (PI)
Amer Soc Nephrology
Identification of the endogenous antigen and development of an ELISA for the detection of autoantibo07/01/2007 - 06/30/2013 (PI)
AMGEN, INC
Identification of the Endogenous Antigen and Development of an ELISA for the Detection of Autoantibo07/01/2007 - 06/30/2009 (PI)
The Halpin Foundation